Loading
Switching from one blood-vessel drug to another after progression gave about six extra weeks, the same small gain as aflibercept.
RAISE randomised 1,072 patients whose metastatic colorectal cancer had progressed during or within six months of first-line bevacizumab, oxaliplatin and a fluoropyrimidine to second-line FOLFIRI with ramucirumab 8 mg/kg or placebo. Median overall survival was 13.3 against 11.7 months. Ramucirumab blocks VEGF receptor 2 rather than the ligand, and the result shows that continued blockade of the pathway after progression helps a little but does not overcome resistance. It is not funded for colorectal cancer in England.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Ramucirumab, Eli Lilly (incl. Loxo), Anti-angiogenic therapy, Monoclonal antibodies.
Shares VELOUR, Ramucirumab, FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
Shares Ramucirumab, Eli Lilly (incl. Loxo), Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR, Anti-angiogenic therapy, Colorectal cancer.
Shares VEGF / VEGFR, Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
Shares Ramucirumab, VEGF / VEGFR, Anti-angiogenic therapy, Monoclonal antibodies.